Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics reported a pivotal quarter marked by the first patient dosing and ongoing enrolment in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating its lead candidate NUZ-001 for ALS, alongside new preclinical data underscoring the drug’s multi-pathway mechanism and potential relevance across a broader range of neurodegenerative disorders. The company also bolstered its financial position with more than $17.5 million in new funding, secured global trademark protection for NEURIZON, and deepened strategic ties with Elanco Animal Health, moves that collectively de-risk its late-stage clinical program and support long-term commercial readiness while reinforcing its industry positioning in neurodegeneration.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is an ASX-listed, clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Huntington’s disease. Its lead drug candidate, NUZ-001, targets multiple protein clearance pathways and is being advanced as a potential therapy in the U.S., its primary value-creation market.
Average Trading Volume: 536,728
Technical Sentiment Signal: Sell
Current Market Cap: A$62.34M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.